British Pharmacists call for regulation on non-medicinal CBD products
pharmafile | December 17, 2019 | News story | Manufacturing and Production | CBD, CBD Oil, CBD Products, cannabis
Pharmacists are calling for more checks on products containing Cannabis derivative cannabidiol (CBD) that are sold in shops across the country.
At the moment cannabidiol oil is classified as a food supplement, and it has been recently added to a range of products like chocolate, coffee, tea and makeup. It’s a brand-new type of food so there is a grace period where it is allowed to be sold in shops, but the Food Standards Agency (FSA) has now asked manufactures to give specific information about the product.
Jasmine Shah from the National Pharmacy Association, which represents hundreds of independent pharmacies, says that pharmacies are also stocking these CBD products. The problem lies in the fact that there is very little research on the effectiveness of CBD products or treatments.
Customers buying CBD products have no guarantees that is contains CBD oil at all, or if it is generally safe for use.
The FSA says that CBD manufacturers have ignored repeated requests for specific information about their products, including manufacturing practices, what the product contains, purity levels and how they know it is safe for human consumption
Shah said that: “It’s for each pharmacist to decide whether it’s suitable to stock a CBD product or not, but in terms of the safety and efficacy of it more research is required.”
According to the manufacturers of CBD products, sales are as much as £300 million currently in the UK.
Conor Kavanagh
Related Content
GW Pharma’s cannabidiol gains EC approval
GW Pharmaceuticals has received European Commission (EC) approval for the type II variation application for …
NHS guidelines on prescription cannabis to be challenged in court
The cannabis guidelines followed by the NHS are set to be challenged in court by …
FDA approves CBD treatment for seizures associated with tuberous sclerosis complex
The FDA has approved Epidiolex (cannabidiol) as a treatment for seizures associated with tuberous sclerosis …